Emergent BioSolutions (NYSE:EBS) Rating Lowered to “Hold” at StockNews.com

Emergent BioSolutions (NYSE:EBS) was downgraded by equities researchers at StockNews.com from a “buy” rating to a “hold” rating in a report released on Saturday.

Other equities analysts also recently issued reports about the stock. Benchmark lifted their price target on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Rodman & Renshaw reiterated a “buy” rating and issued a $16.00 target price on shares of Emergent BioSolutions in a research note on Friday, September 13th.

Emergent BioSolutions Stock Performance

Emergent BioSolutions stock opened at $8.27 on Friday. Emergent BioSolutions has a 52-week low of $1.42 and a 52-week high of $15.10. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47. The stock has a fifty day moving average price of $9.21 and a two-hundred day moving average price of $8.89. The firm has a market capitalization of $448.10 million, a P/E ratio of -2.02 and a beta of 1.59.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in EBS. Meeder Asset Management Inc. acquired a new position in Emergent BioSolutions during the 2nd quarter worth $41,000. Verus Capital Partners LLC acquired a new position in shares of Emergent BioSolutions during the second quarter valued at $68,000. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Emergent BioSolutions during the second quarter valued at $93,000. Stifel Financial Corp bought a new position in Emergent BioSolutions in the third quarter valued at about $96,000. Finally, Morse Asset Management Inc acquired a new stake in Emergent BioSolutions in the second quarter worth about $97,000. Institutional investors and hedge funds own 78.40% of the company’s stock.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.